Strategic Partnerships Loxo has demonstrated openness to external collaboration through past partnerships with Foghorntx, Kumquat Biosciences, and Merus, and sits within Lilly, which expands access to larger resources while maintaining a biotech-like focus on impactful oncology programs. This suggests opportunities to pitch partner-enabled platforms (e.g., gene therapy, bispecifics, or companion diagnostics) to support early-stage assets and accelerate development with CROs, diagnostic firms, and biotech collaborators.

Biomarker Diagnostics The emphasis on clinical biomarkers, laboratories, and diagnostics development signals ongoing demand for biomarker assay services, companion diagnostics, and centralized analytics. Potential sales angles include CROs offering biomarker testing, CLIA-certified labs, sequencing providers, and diagnostic developers that can co-develop assays or provide diagnostic readiness for trials.

Global Footprint Global presence enables multinational trial support and cross-market regulatory considerations. Opportunities exist to partner with regional CROs, regulatory affairs consultants, and logistics providers to streamline global trial execution, country-specific manufacturing and supply, and local support for Lilly’s oncology programs.

Supply Chain Experience with a mature supply chain evidenced by use of major logistics providers and compliance tooling points to demand for specialized clinical supply services, cold-chain logistics, serialization, and supply-chain software integrations to ensure safe and compliant delivery of investigational medicines and diagnostic components.

Clinical Data The focus on early clinical activity and patient-centered oncology medicines creates a need for robust data management and analytics capabilities. Opportunities include data capture systems, EDC/clinical data management, biostatistical programming, biomarker data integration, and real-world evidence collaborations to de-risk development and demonstrate value of new therapies.